AZN AstraZeneca PLC Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:05
Sep 04
Sep 04
AstraZeneca receives FDA approval for its breast cancer pill.
AstraZeneca receives FDA approval for its breast cancer pill, marking a regulatory win after the agency's advisory panel previously voted against the medicine.
19:49
Sep 04
Sep 04
US FDA grants accelerated approval to AstraZeneca's Etcamah for advanced breast cancer.
US FDA grants accelerated approval to AstraZeneca's Etcamah for advanced breast cancer with ESR1 mutation.
19:44
Sep 04
Sep 04
US FDA grants accelerated approval to AstraZeneca's Etcamah for advanced breast cancer.
US FDA grants accelerated approval to AstraZeneca's Etcamah for advanced breast cancer with ESR1 mutation.
16:23
Aug 17
Aug 17
AstraZeneca pipeline risks make buying difficult.
AstraZeneca's failed late-stage lung cancer trial against the Keytruda standard of care, along with expected negative upcoming data and confusing M&A chatter with Bristol-Myers, makes it difficult to see a reason to be buying the stock.
MED
13:00
Aug 17
Aug 17
Highlights largest single-fund new positions.
Highlights largest single-fund new positions for Q2 2026, no directional view.
MED
10:01
Aug 17
Aug 17
AstraZeneca ends Phase 3 lung cancer trial
AstraZeneca terminated a Phase 3 lung cancer drug trial after a review; no reason for termination or directional view stated.
LOW
06:31
Aug 17
Aug 17
AstraZeneca announces that its DESTINY-Lung04 study will continue evaluating overall survival.
AstraZeneca announces that its DESTINY-Lung04 study will continue evaluating overall survival as an ongoing clinical trial endpoint.
06:06
Aug 17
Aug 17
AstraZeneca confirms that its other phase III volrustomig trials remain on track according.
AstraZeneca confirms that its other phase III volrustomig trials remain on track according to the company statement.
11:16
Aug 11
Aug 11
The author speculates on AstraZeneca's next acquisition target after avoiding a mega merger.
The author speculates on AstraZeneca's next acquisition target after avoiding a mega merger, but offers no directional position or trade call.
LOW
11:02
Aug 11
Aug 11
AZN/BMY deal collapsed; $80B target reaffirmed
AZN/BMY deal collapsed August 3 after months of near-agreement talks; investor revolt and government intervention cited; Soriot reaffirms $80B 2030 revenue target independently.
LOW
12:00
Aug 06
Aug 06
AZN advised to acquire INSM, RVMD, ABVX
Author frames AZN as the natural acquirer of INSM/RVMD/ABVX, arguing the trifecta at ~$100B with premiums is superior capital allocation to a BMY deal — no directional position on AZN stock stated.
LOW
12:12
Aug 05
Aug 05
AstraZeneca-Bristol Myers deal discussions denied
Reports a senior AZN source denying AstraZeneca-Bristol Myers deal talks; no directional stance stated.
LOW
12:05
Aug 05
Aug 05
AstraZeneca and Bristol Myers Squibb deny any deal discussions.
AstraZeneca and Bristol Myers Squibb deny any deal discussions, with a senior source stating no deal was ever on the table.
19:37
Aug 03
Aug 03
Author speculates on FTC concerns about a potential AZN-BMY merger citing cultural.
Author speculates on FTC concerns about a potential AZN-BMY merger citing cultural and workforce issues, but offers no personal position or trade call.
LOW
17:41
Aug 03
Aug 03
Merger destroys Astra value; avoid.
A merger between AstraZeneca and Bristol-Myers would destroy value for AstraZeneca shareholders. The deal lacks strategic logic, would dilute earnings growth and create uncertainty, and Astra does not need it. The market is punishing Astra shares accordingly.
MED
16:27
Aug 03
Aug 03
AstraZeneca investors raise concerns over the company's mega-merger talks according.
AstraZeneca investors raise concerns over the company's mega-merger talks according to a Financial Times report.
15:57
Aug 03
Aug 03
AstraZeneca and Bristol-Myers Squibb are in preliminary merger talks creating a potential $400B.
AstraZeneca and Bristol-Myers Squibb are in preliminary merger talks creating a potential $400B pharma powerhouse, but the Seeking Alpha rating remains a neutral hold on AZN.
15:38
Aug 03
Aug 03
AZN buying BMY would destroy value
A potential AstraZeneca acquisition of Bristol-Myers makes no sense because AstraZeneca has strong double-digit growth through 2030 while Bristol-Myers faces patent expiries and flat to declining earnings; the deal would dilute AstraZeneca's growth, create uncertainty, destroy shareholder value, and the international access rationale is weak.
HIGH
15:10
Aug 03
Aug 03
AstraZeneca and Bristol-Myers Squibb are reportedly considering a $400 billion merger that.
AstraZeneca and Bristol-Myers Squibb are reportedly considering a $400 billion merger that analysts suggest could face significant complications.
15:08
Aug 03
Aug 03
Author notes both Bristol-Myers Squibb and AstraZeneca are down with a laughing emoji.
Author notes both Bristol-Myers Squibb and AstraZeneca are down with a laughing emoji, offering no directional thesis or position.
LOW
13:50
Aug 03
Aug 03
AstraZeneca investors expressed disapproval of a proposed 400 billion dollar merger.
AstraZeneca investors expressed disapproval of a proposed 400 billion dollar merger with Bristol-Myers Squibb, according to a report from the news wire.
12:45
Aug 03
Aug 03
AstraZeneca and Bristol-Myers Squibb are reportedly considering a $400 billion merger that.
AstraZeneca and Bristol-Myers Squibb are reportedly considering a $400 billion merger that could face significant complications according to an opinion piece.
12:11
Aug 03
Aug 03
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers.
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers, a GME convertible exchange, a Curium-Lantheus deal, BABA's AI launch, and multiple analyst rating changes across several stocks.
11:45
Aug 03
Aug 03
Jefferies analysts question the strategic logic of a potential AstraZeneca and Bristol Myers.
Jefferies analysts question the strategic logic of a potential AstraZeneca and Bristol Myers merger, calling the reported $400 billion pharma megadeal a head scratcher.
11:31
Aug 03
Aug 03
AstraZeneca and Bristol Myers Squibb reportedly held merger talks that would create a nearly.
AstraZeneca and Bristol Myers Squibb reportedly held merger talks that would create a nearly 400 billion dollar pharmaceutical giant.
08:07
Aug 03
Aug 03
Bristol-Myers Squibb shares rise 3.8% in premarket trading following reports of potential deal.
Bristol-Myers Squibb shares rise 3.8% in premarket trading following reports of potential deal talks between the company and AstraZeneca.
07:09
Aug 03
Aug 03
AstraZeneca shares fall over seven percent after reports of preliminary merger talks.
AstraZeneca shares fall over seven percent after reports of preliminary merger talks with Bristol Myers Squibb regarding a possible combination.
01:04
Aug 03
Aug 03
AZN-BMY $400bn tie-up talks reported.
Reports AstraZeneca and Bristol Myers Squibb are in talks over a $400bn combination. Substantive M&A development, but author gives no directional view.
LOW
22:42
Aug 02
Aug 02
AstraZeneca no longer a potential acquirer.
Author notes AstraZeneca is no longer in the running as a potential acquirer for ABVX.
MED
21:40
Aug 02
Aug 02
AstraZeneca has reportedly explored acquiring Bristol Myers in a potential megadeal that would.
AstraZeneca has reportedly explored acquiring Bristol Myers in a potential megadeal that would create one of the world’s largest drugmakers.
About AZN Analyst Coverage
Buzzberg tracks AZN (AstraZeneca PLC) across 14 sources. 6 bullish vs 0 bearish calls from 29 analysts. Sentiment: predominantly bullish (7%). 87 total trade ideas tracked. Past 7 days: 3 watch. Latest voices: Bloomberg, FirstSquawk, LiveSquawk.